RxDoctor Payments Data

Courtney St James, MD

Family Medicine · Orange City, FLNPI 1366853202

Payments from drug & device makers

$6,791in general payments, 2019–2025

Across 372 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amarin Pharma, Inc.$1K
  • AbbVie$1K
  • AstraZeneca$754
  • Boehringer Ingelheim$440
  • Lilly USA, LLC$405
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$6,68398%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,791 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$157,727
Medicare patients
234
Services billed
2,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$84,595
EliquisApixaban66$63,709
JardianceEmpagliflozin18$23,765
MyrbetriqMirabegron20$21,501
JanuviaSitagliptin Phosphate13$20,779
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,579
Repatha SureclickEvolocumab16$15,776
XareltoRivaroxaban12$14,547
Trijardy XrEmpaglifloz/Linaglip/Metformin12$7,046
Omeprazole172$3,090
Atorvastatin Calcium313$2,913
SynthroidLevothyroxine Sodium34$2,686
Gabapentin137$2,672
Amlodipine Besylate293$2,507
Rosuvastatin Calcium167$2,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,514$84,59549 claims
PfizerEliquis$210$63,70966 claims
Boehringer IngelheimJardiance, Trijardy Xr$440$30,81130 claims
Astellas Pharma US IncMyrbetriq$142$21,50120 claims
MerckJanuvia$68$20,77913 claims
GSKTrelegy Ellipta$153$18,57924 claims
Johnson & JohnsonXarelto$106$14,54712 claims
AbbVieSynthroid$1,105$2,68634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →